Table 2.

All-cause mortality and clinically overt cardiotoxicity in studies using carvedilol

Study	All-cause mortality		Clinically overt cardiotoxicity
	Carvedilol	Placebo	Cutoff point	Carvedilol	Placebo
N. K. [24]	1 (4%)	4 (16%)	LVEF < 50%	1 (4%)	5 (20%)
R.J. [25]	6 (22%)	5 (18%)	LVEF < 50%	1 (4%)	3 (12%)
A. E. [26]	0	0	Interrupted chemotherapy due to cardiotoxicity	0	0
M. N. [27]	1 (2%)	0	LVEF < 40%	2 (4%)	3 (7%)
R. S. [29]	2 (9%) [12.5 mg carvedilol]	4 (18%)	Systolic cardiomyopathy (no specification)	5 (23%) [12.5 mg carvedilol] 1 (5%) [25 mg carvedilol]	5 (23%)
	1 (4%) [25 mg carvedilol]		Diastolic cardiomyopathy (no specification)	3 (14%) [12.5 mg carvedilol] 3 (14%) [25 mg carvedilol]	5 (23%)
M. A. [28]	2 (2%)	2 (2%)	LVEF reduction ≥ 10%	14 (14.5%)	13 (13.5%)
			LVEF decreased to < 55%	0	1 (1%)

The cutoff point of clinically overt cardiotoxicity is based on the criteria used in individual study